Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: Disclosed is a method and apparatus for determining a concentration of a glycopeptide antibiotic containing a phenol moiety such as Vancomycin in a complex sample matrix by extracting the glycopeptide antibiotic from a metered portion of the complex sample matrix by exposing said metered portion to an extraction material having an affinity with the glycopeptide antibiotic; and exposing the extraction material to a metered portion of an eluent for releasing the glycopeptide antibiotic from the extraction material; and by determining a concentration of the glycopeptide antibiotic by adding a Gibbs reagent (2,6 dichloroquinone-4chloroimide) to the metered portion of the complex sample matrix or the eluent; activating the Gibbs reagent and, after the reaction between the activated Gibbs reagent and the antibiotic has stabilized; detecting the reaction product of the activated Gibbs reagent and the antibiotic in said eluent; and determining the concentration of the antibiotic in the complex sample matrix from the

Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.

Abstract: Provided herein is a probe for ultrasound imaging of tissue. The probe comprises an optical relay having an optically absorbing coating at the distal end of the probe for generating ultrasound from excitation light via the photoacoustic effect, wherein the generated ultrasound propagates as an ultrasound beam into the tissue; and an ultrasound receiver separate from the optical relay. The optical relay is configured to receive as input a time-varying spatial pattern of excitation light at the proximal end of the probe and to transmit the excitation light to the distal end of the probe to illuminate the optically absorbing coating in accordance with said time-varying spatial pattern, thereby generating ultrasound from the excitation light via the photoacoustic effect to propagate as a scanning ultrasound beam into the tissue. The ultrasound receiver is configured to receive reflections of the ultrasound from tissue. Such an ultrasound probe may be incorporated, for example, into a transseptal puncture needle.

Abstract: The disclosure relates to methods for obtaining angiogenic factors, as well as to methods of treating cardiovascular disease and methods for stimulating angiogenesis.

Abstract: The invention provides an antibody or fragment thereof that specifically binds to human Lrg1.

Abstract: The invention provides porous carbon particles for use in the treatment or prevention of liver disease, wherein at least 20% of the total pore volume is made up of pores having a mean diameter of from 2 to 200 nm and/or wherein the particles comprise micropores of diameter 2 nm or less and small macropores of diameter 50 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 50 nm, and substantially no large macropores of diameter greater than 500 nm.

Abstract: Lentiviral packaging cells and methods for producing the same are provided herein. Specifically, lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are provided. Methods for producing lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are described.

Abstract: The present invention provides an audio-visual dialogue system that allows a user to create an ‘avatar’ which may be customised to look and sound a particular way. The avatar may be created to resemble, for example, a person, animal or mythical creature, and generated to have a variable voice which may be female or male. The system then employs a real-time voice conversion in order to transform any audio input, for example, spoken word, into a target voice that is selected and customised by the user. The system is arranged to facially animate the avatar using a real-time lip-synching algorithm such that the generated avatar and the target voice are synchronised.

Abstract: A semiconductor device comprising a silicon substrate on which is grown a <100 nm thick epilayer of AlAs or related compound, followed by a compound semiconductor other than GaN buffer layer. Further III-V compound semiconductor structures can be epitaxially grown on top. The AlAs epilayer reduces the formation and propagation of defects from the interface with the silicon, and so can improve the performance of an active structure grown on top.

Abstract: A method of measuring surface curvature comprises forming an intensity distribution defined by Fresnel diffraction, wherein said intensity distribution is formed by electromagnetic radiation reflected from a surface, obtaining data for the intensity distribution and determining information relating to the curvature of the surface using the obtained data.

Abstract: The invention provides inhibitors of hypoxia-inducible factors (HIF), and their use in the prevention or inhibition of diseases characterised by abnormal HIF activity or levels, such as tumour progression, and the treatment of cancer. The invention encompasses pharmaceutical compositions with a mechanism of action for blocking elevated HIF activity in diseases, such as cancer.

Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.

Abstract: A prosthesis delivery system comprises a sheath defining an axial direction; at least one tether movable axially relative to the sheath; and a holder movable axially within the sheath, configured to constrain radially the tether(s). Collapsing the prosthesis to a collapsed state in the sheath involves constraining radially with a holder the tether(s), attached to the prosthesis; and moving the tether(s) and the holder axially within the sheath such that the prosthesis is forced to collapse into the sheath and the holder is retracted into the sheath.

Abstract: A system and method are provided for using a computer system to assist in planning a trajectory (960A, 960B) for a surgical insertion into a skull. The method comprises providing the computer system with a three-dimensional representation of the skull and of critical objects located within the skull, wherein the critical objects comprise anatomical features to be avoided during the surgical insertion. The method further comprises providing the computer system with a target location (770, 970) for the insertion within the skull. The method further comprises generating by the computer system a first set comprising a plurality of entry points, each entry point (760) representing a surface location on the skull, and each entry point (760) being associated (2D) with a trajectory (960A, 960B) from the entry point (760) to the target location (770, 970).

Abstract: The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: wherein: V is N or CR3; X is N or CR4; Y is N or CR5; Z is N or CR6; B is —(C?O)R1, a 5- to 10-membered heteroaryl group, or a group -L??-NRR?, wherein R and R? are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; R1 is a 5- to 10-membered heterocyclyl group, or —OR?, wherein R? is a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group, or R1 is a proteinogenic ? amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the ? amino group, which amino acid is optionally esterified at the ? carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group, or R1 is —NR?R??, —NRIV-L??-CONR?R??, or —NRIV-L??-COOR, wherein R, R?, R?? and RIV are the same or different and ea

Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.